CClinicalTrials.gg
Status unknownNCT03329287Updated Nov 1, 2017

Simplified Cognitive Behavioral Therapy for Generalized Anxiety Disorder and Depression

An interventional study of SCBT and SSRIs and/or SNRIs in Generalized Anxiety Disorder and Major Depressive Disorder, sponsored by Shanghai Mental Health Center. Status unknown at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2017-11-01.

Sponsored by Shanghai Mental Health Center · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This trial attempts to evaluate the treatment efficacy of Simplified Cognitive Behavioral Therapy (SCBT) and its safety among schizophrenia patients. Half of participants will be randomized to accept SCBT.

Read the detailed description

The investigators have developed a simplified but standardized set of cognitive behavioral treatment (including the therapist's manual and patient self-help manual) for the patients of generalized anxiety disorder and depression, known as Simplified Cognitive Behavioral Therapy (SCBT). SCBT is the main psychological intervention of this study. The aim of this study is to verify its efficacy and applicability using a multi-center, randomized, placebo controlled and single-blind design, and to optimize the treatment program. The investigators hypothesize that SCBT is effective in patients with depression or anxiety, and the manual is easily-operated for the therapists.

02

Conditions studied

  • Generalized Anxiety Disorder
  • Major Depressive Disorder

Keywords

  • Simplified Cognitive Behavioral Therapy (SCBT)
  • Generalized Anxiety Disorder
  • Depression
  • Operating manual
  • Efficacy
03

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

    1. Adults aged 18-60 years old, male and female; 2. With primary school or above education levels; 3. Without vision, hearing or communication difficulties; 4. DSM-V diagnosis of generalized anxiety disorder and/or major depressive disorder; 5. HAMA-14 score greater than or equal to 14 points, less than 29 pionts; HAMD-17 score greater than or equal to 7 points, less than 24 points; 6. GAD-7 score greater than or equal to 5 points; PHQ-9 score greater than or equal to 5 points; 7. In the last 2 months, did not accept other forms of psychological treatment, or treatment is ineffective; 8. Voluntarily participate in and sign informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Suffering from serious physical illness;
  2. Having self-injurious behavior, suicidal tendencies;
  3. Having bipolar disorder;
  4. Having psychotic symptoms;
  5. Having obsessive-compulsive disorder, post-traumatic stress disorder;
  6. Pregnant women or lactating women.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    SCBT + Drug

    Participants receive SCBT at a frequency of twice a week in the first 4 weeks, and once a week in the following 4 weeks. They also take SSRIs and/or SNRIs through the trial at a recommended dosage.

    Behavioral: SCBT · Drug: SSRIs and/or SNRIs

  • Active comparator
    Psychological Placebo + Drug

    Participants receive supportive and relaxation therapy at a frequency of twice a week in the first 4 weeks, and once a week in the following 4 weeks. They also take SSRIs and/or SNRIs through the trial at a recommended dosage.

    Drug: SSRIs and/or SNRIs · Behavioral: Psychological Placebo

  • Active comparator
    Drug

    Participants only take SSRIs and/or SNRIs through the trial at a recommended dosage.

    Drug: SSRIs and/or SNRIs

Interventions

  • BehavioralSCBT

    SCBT, one hour per session.

  • DrugSSRIs and/or SNRIs

    SSRIs and/or SNRIs at a recommended dosage.

  • BehavioralPsychological Placebo

    Supportive and relaxation therapy, one our per session.

05

What researchers measure

Primary outcomes

  1. changes of The Hamilton Depression Scale (HAMD-17)

    Scale total range is 52. Lower score represents a better outcome.

    Time frame: At baseline, 2-week, 4-week, 6-week, 8-week, 12-week, 20-week, 32-week and 56-week.

  2. changes of The Hamilton Anxiety Scale (HAMA-14)

    Scale total range is 56. Lower score represents a better outcome.

    Time frame: At baseline, 2-week, 4-week, 6-week, 8-week, 12-week, 20-week, 32-week and 56-week.

Secondary outcomes

  1. changes of The Patient Health Questionnaire (PHQ-9)

    Scale total range is 27. Lower score represents a better outcome.

    Time frame: At baseline, 2-week, 4-week, 6-week, 8-week, 12-week, 20-week, 32-week and 56-week.

  2. changes of The GAD-7

    Scale total range is 21. Lower score represents a better outcome.

    Time frame: At baseline, 2-week, 4-week, 6-week, 8-week, 12-week, 20-week, 32-week and 56-week.

  3. changes of The Mos 36-item Short Form Health Survey (SF-36)

    It has nine dimensions, each dimension has an independent fractional formula.

    Time frame: At baseline, 4-week, 8-week, 12-week, 20-week, 32-week and 56-week.

  4. changes of Treatment Emergent Symptom Scale (TESS)

    Evaluation of side effects caused by various psychotropic drugs.

    Time frame: At baseline, 2-week, 4-week, 6-week, 8-week, 12-week, 20-week, 32-week and 56-week.

  5. changes of Clinical Global Impression (CGI)

    Evaluation of clinical efficacy. Lower score represents a better outcome.

    Time frame: At baseline, 2-week, 4-week, 6-week, 8-week, 12-week, 20-week, 32-week and 56-week.

06

Study locations

1 of 1 sites recruiting
  • Shanghai Mental Health Center
    Shanghai, Shanghai 200030, China
    • Chunbo Li, PHD · Contact · chunbo_li@163.com · 86-21-34773243
    • Chunbo Li, PHD · Principal investigator
    Recruiting
07

References and documents

Individual participant data

Plan to share: No — No plan to share IPD data

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03329287
Lead sponsor
Shanghai Mental Health Center
Collaborators
Changhai Hospital, Shanghai 10th People's Hospital, Tongji Hospital, Fudan University, Second Hospital of Shanxi Medical University
Responsible party
Sponsor
First posted
Nov 1, 2017
Start date
Jul 1, 2017
Primary completion
Mar 30, 2018 (estimated)
Completion
Jun 30, 2018 (estimated)
Last update
Nov 1, 2017

Study contacts

Chunbo Li, PHD
Contact
chunbo_li@163.com
86-21-34773243
Chunbo Li, PHD
principal investigator · Shanghai Mental Health Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion